Reports as of December 31, Corvus had cash, cash equivalents and marketable securities of $52.M as compared to $27.1M as of December 31, 2023.

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...

Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...

Q4 2024 Earnings Call Transcript March 25, 2025 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

Insiders who purchased Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) shares in the past 12 months are unlikely to be deeply impacted by the stock's 16% decline over the past week. After taking the ...

Potential Additional Cash from Warrant Exercises: Approximately $41 million. Corvus Pharmaceuticals Inc (NASDAQ:CRVS) reported a 39% objective response rate in their phase one trial of ...

This work was recently published in January in the journal Nature 637:1207, 2025. Angel Pharmaceuticals, Corvus' partner in China, continues to monitor patients in an expansion cohort of its Phase ...

BURLINGAME, Calif. (AP) — BURLINGAME, Calif. (AP) — Corvus Pharmaceuticals Inc. (CRVS) on Tuesday reported a loss of $12.1 million in its fourth quarter. The Burlingame, California-based ...

The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 12 cents per share. For the year, the company ...

BURLINGAME, Calif. (AP) — BURLINGAME, Calif. (AP) — Corvus Pharmaceuticals Inc. (CRVS) on Tuesday reported a loss of $12.1 million in its fourth quarter. On a per-share basis, the Burlingame ...